Robert Beardsley
President & CEO Cirius Therapeutics
Seminars
Thursday 16th April 2026
Redefining the Patient Journey by Leveraging Oral MPC Modulation to Enhance GLP-1 Tolerability and Enhance Metabolic Health
2:00 pm
- Utilizing a noveloral Mitochondrial Pyruvate Carrier (MPC)inhibitor with GLP-1 Receptor Agonists, as evidenced by preclinical and early clinical data showing enhanced metabolic control (improved insulin sensitivity, reduced liver fat) and synergistic efficacy in reducing underlying metabolic dysfunction in Type 2 Diabetes and MASH
- Focusing on the MPC modulator’s potential to preserve lean mass and muscle function while optimizing fat, establishing long-term patient health and adherence that is critical to redefining the patient journey beyond mere weight reduction
- Defining the strategy for next-generation metabolic therapeutics that combine a novel oral, non-incretin mechanism with incretinsto significantly enhance patient comfort and compliance by allowing for lower, better-tolerated doses of the GLP-1 component and generating best-in-class outcomes
